Zahed Subhan, CEO of Marillion Pharmaceuticals, said: “177Lu-AMBA is a targeted radiotherapeutic that utilizes an innovative receptor-based technology. In contrast to traditional modes of treatment for advanced cancers, this unique targeting capability means that 177Lu-AMBA is able to home in on tumor cells and spare normal tissues.
“In addition, up to 70% of patients with prostate cancer have bone metastases which cause unrelenting pain. Early clinical trials have shown that these metastases may also be effectively targeted by 177Lu-AMBA.”